Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes

Biochim Biophys Acta. 2011 Mar;1811(3):153-62. doi: 10.1016/j.bbalip.2010.11.011. Epub 2010 Dec 9.

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is secreted from adipose tissue and is considered to be a risk factor for both atherosclerosis and insulin resistance. Here we report for the first time that PAI-1 expression is enhanced by oxidized low-density lipoprotein (OxLDL) and its lipid component lysophosphatidylcholine (LPC) in mouse 3T3-L1 adipocytes. In fully differentiated 3T3-L1 cells, OxLDL treatment increased the mRNA expression and protein secretion of PAI-1 in a dose- and time-dependent manner, whereas native LDL had no effect. The addition of an anti-CD36 antibody suppressed OxLDL-stimulated PAI-1 expression by 50%, suggesting that adipose-derived CD36 contributes to roughly half of the PAI-1 expression stimulated by OxLDL. In addition, pharmacological experiments showed that the OxLDL-stimulated enhancement in PAI-1 expression was mediated through the generation of reactive oxygen species (ROS) and phosphorylation of extracellular signal-regulated kinase 1/2. Furthermore, LPC, a major lipid component of OxLDL, was responsible for the enhanced expression of PAI-1 as phospholipase A(2)-treated acetyl LDL, which generates LPC, strongly stimulated PAI-1 expression, whereas acetyl LDL itself had no such activity. These data demonstrate that the uptake of OxLDL and, in particular, its lipid component LPC into adipocytes triggers aberrant ROS-mediated PAI-1 expression, which may be involved in the pathogenesis of metabolic syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / metabolism*
  • Adipocytes / pathology
  • Animals
  • Antibodies / pharmacology
  • Dose-Response Relationship, Drug
  • Enzyme Activation / drug effects
  • Gene Expression Regulation / drug effects
  • Lipoproteins, LDL / pharmacology*
  • Lysophosphatidylcholines / pharmacology*
  • Metabolic Syndrome / metabolism
  • Metabolic Syndrome / pathology
  • Mice
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Plasminogen Activator Inhibitor 1 / biosynthesis*
  • Reactive Oxygen Species / metabolism*
  • Time Factors

Substances

  • Antibodies
  • Lipoproteins, LDL
  • Lysophosphatidylcholines
  • Plasminogen Activator Inhibitor 1
  • Reactive Oxygen Species
  • oxidized low density lipoprotein
  • Mitogen-Activated Protein Kinase 3